MA31920B1 - 4-(4-cyano-2-thioaryle)-dihydropyrimidinone et son utilisation - Google Patents
4-(4-cyano-2-thioaryle)-dihydropyrimidinone et son utilisationInfo
- Publication number
- MA31920B1 MA31920B1 MA32921A MA32921A MA31920B1 MA 31920 B1 MA31920 B1 MA 31920B1 MA 32921 A MA32921 A MA 32921A MA 32921 A MA32921 A MA 32921A MA 31920 B1 MA31920 B1 MA 31920B1
- Authority
- MA
- Morocco
- Prior art keywords
- thioaryl
- cyano
- dihydropyrimidinone
- prevention
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
- C07D239/10—Oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
L'INVENTION CONCERNE : DE NOUVEAUX DÉRIVÉS DE 4-(4-CYANO-2-THIOARYLE)-DIHYDROPYRIMIDINE-2-ONE : DES PROCÉDÉS POUR LEUR FABRICATION ; LEUR UTILISATION SEULS OU EN COMBINAISONS POUR LE TRAITEMENT ET/OU LA PRÉVENTION DE MALADIES ET LEUR UTILISATION POUR LA FABRICATION DE MÉDICAMENTS POUR LE TRAITEMENT ET/OU LA PRÉVENTION DE MALADIES, EN PARTICULIER POUR LE TRAITEMENT ET/OU LA PRÉVENTION DE MALADIES DES POUMONS ET DU SYSTÈME CARDIOVASCULAIRE.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102007061766A DE102007061766A1 (de) | 2007-12-20 | 2007-12-20 | 4-(4-Cyano-2-thioaryl)-dihydropyrimidinone und ihre Verwendung |
DE102008022521A DE102008022521A1 (de) | 2008-05-07 | 2008-05-07 | 1,4-Diaryl-pyrimidopyridazin-2,5-dione und ihre Verwendung |
DE102008052013A DE102008052013A1 (de) | 2008-10-17 | 2008-10-17 | 4-(4-Cyano-2-thioaryl)-dihydropyrimidinone und ihre Verwendung |
PCT/EP2008/010411 WO2009080199A1 (fr) | 2007-12-20 | 2008-12-09 | 4-(4-cyano-2-thioaryle)-dihydropyrimidinone et son utilisation |
Publications (1)
Publication Number | Publication Date |
---|---|
MA31920B1 true MA31920B1 (fr) | 2010-12-01 |
Family
ID=40394273
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA32921A MA31920B1 (fr) | 2007-12-20 | 2010-06-16 | 4-(4-cyano-2-thioaryle)-dihydropyrimidinone et son utilisation |
Country Status (39)
Country | Link |
---|---|
US (3) | US8288402B2 (fr) |
EP (1) | EP2234985B1 (fr) |
JP (1) | JP5519526B2 (fr) |
KR (2) | KR101649381B1 (fr) |
CN (2) | CN103204815B (fr) |
AR (1) | AR069765A1 (fr) |
AT (1) | ATE548355T1 (fr) |
AU (1) | AU2008340733B9 (fr) |
BR (1) | BRPI0821027B8 (fr) |
CA (1) | CA2709786C (fr) |
CL (1) | CL2008003691A1 (fr) |
CO (1) | CO6280490A2 (fr) |
CR (1) | CR11472A (fr) |
CY (1) | CY1112813T1 (fr) |
DK (1) | DK2234985T3 (fr) |
DO (1) | DOP2010000165A (fr) |
EC (1) | ECSP10010216A (fr) |
ES (1) | ES2382143T3 (fr) |
HK (2) | HK1146485A1 (fr) |
HR (1) | HRP20120457T1 (fr) |
IL (2) | IL205742A (fr) |
JO (1) | JO2756B1 (fr) |
MA (1) | MA31920B1 (fr) |
MX (1) | MX2010006033A (fr) |
MY (1) | MY150285A (fr) |
NZ (1) | NZ586263A (fr) |
PE (1) | PE20091429A1 (fr) |
PL (1) | PL2234985T3 (fr) |
PT (1) | PT2234985E (fr) |
RS (1) | RS52270B (fr) |
RU (1) | RU2497813C2 (fr) |
SG (2) | SG10201604819TA (fr) |
SI (1) | SI2234985T1 (fr) |
SV (1) | SV2010003581A (fr) |
TN (1) | TN2010000288A1 (fr) |
TW (1) | TWI455715B (fr) |
UY (1) | UY31526A1 (fr) |
WO (1) | WO2009080199A1 (fr) |
ZA (1) | ZA201004239B (fr) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5672699B2 (ja) | 2007-04-11 | 2015-02-18 | 味の素株式会社 | 血糖降下作用化合物のスクリーニング法 |
BRPI0821027B8 (pt) * | 2007-12-20 | 2021-05-25 | Bayer Ip Gmbh | 4-(4-ciano-2-tioaril)di-hidropirimidinonas para tratamento e/ou prevenção de lesões do pulmão e do sistema cardiovascular, seu processo de preparação e seu uso, e medicamento |
DE102009016553A1 (de) * | 2009-04-06 | 2010-10-07 | Bayer Schering Pharma Aktiengesellschaft | Sulfonamid- und Sulfoximin-substituierte Diaryldihydropyrimidinone und ihre Verwendung |
GB201004178D0 (en) * | 2010-03-12 | 2010-04-28 | Pulmagen Therapeutics Inflamma | Enzyme inhibitors |
GB201004179D0 (en) * | 2010-03-12 | 2010-04-28 | Pulmagen Therapeutics Inflamma | Enzyme inhibitors |
DE102010030187A1 (de) | 2010-06-16 | 2011-12-22 | Bayer Schering Pharma Aktiengesellschaft | 4-Cyan-2-sulfonylphenyl)pyrazolyl-substituierte Pyridinone und Pyrazinone und ihre Verwendung |
WO2013033003A1 (fr) * | 2011-08-26 | 2013-03-07 | Southern Research Institute | Inhibiteurs de la réplication du vih |
CN103373951B (zh) * | 2012-04-28 | 2016-03-09 | 上海医药工业研究院 | 一种拉帕替尼中间体的制备方法 |
AU2014205483B2 (en) | 2013-01-10 | 2017-11-30 | Gilead Sciences, Inc. | Non-selective kinase inhibitors |
US20140221335A1 (en) * | 2013-02-06 | 2014-08-07 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
US9115093B2 (en) | 2013-03-04 | 2015-08-25 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
CN111743901B (zh) | 2013-10-11 | 2023-09-12 | 普尔莫凯恩股份有限公司 | 喷雾干燥制剂 |
USRE47493E1 (en) | 2014-02-20 | 2019-07-09 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
US20170119776A1 (en) | 2014-04-03 | 2017-05-04 | Bayer Pharma Aktiengesellschaft | Chiral 2,5-disubstituted cyclopentanecarboxylic acid derivatives and use thereof |
WO2015150363A1 (fr) | 2014-04-03 | 2015-10-08 | Bayer Pharma Aktiengesellschaft | Acides cyclopentanecarboxyliques à disubstitution 2,5 et leur utilisation |
CA2944614A1 (fr) | 2014-04-03 | 2015-10-08 | Bayer Pharma Aktiengesellschaft | Acides cyclopentanecarboxyliques a disubstitution 2,5 pour traiter des maladies des voies respiratoires |
US9458113B2 (en) * | 2014-07-31 | 2016-10-04 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
US9657015B2 (en) | 2014-07-31 | 2017-05-23 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
US9440930B2 (en) * | 2014-07-31 | 2016-09-13 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
US9475779B2 (en) | 2014-07-31 | 2016-10-25 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
US9290457B2 (en) * | 2014-07-31 | 2016-03-22 | Boehringer Ingelheim International Gmbh | Substituted dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
WO2016050835A2 (fr) * | 2014-10-02 | 2016-04-07 | Ruprecht-Karls-Universität Heidelberg | Inhibiteurs sélectifs de l'élastase neutrophilique pour traiter des états de douleur neuropathique et de douleur chronique comprenant une composante neuropathique |
KR20170129191A (ko) | 2015-03-18 | 2017-11-24 | 바이엘 파마 악티엔게젤샤프트 | (4s)-4-[4-사이아노-2-(메틸설폰일)페닐]-3,6-다이메틸-2-옥소-1-[3-(트라이플루오로메틸)페닐]-1,2,3,4-테트라하이드로 피리미딘-5-카보나이트릴의 생성 방법 |
WO2016176399A1 (fr) * | 2015-04-28 | 2016-11-03 | Stc.Unm | Compositions et méthodes pour le traitement de l'hypertension pulmonaire |
WO2017081044A1 (fr) | 2015-11-13 | 2017-05-18 | Bayer Pharma Aktiengesellschaft | 4-(4-cyano-2-thioaryle)-dihydropyrimidinones destinées au traitement de plaies chroniques |
KR102543227B1 (ko) | 2016-10-27 | 2023-06-13 | 풀모킨 인코포레이티드 | 폐고혈압을 치료하기 위한 병용 요법 |
US9856232B1 (en) | 2017-06-20 | 2018-01-02 | King Saud University | Dihydropyrimidinone derivatives |
WO2019209738A1 (fr) * | 2018-04-24 | 2019-10-31 | Ph Pharma Co., Ltd. | Utilisation d'inhibiteurs d'élastase neutrophile dans une maladie hépatique |
GB201820450D0 (en) * | 2018-12-14 | 2019-01-30 | Z Factor Ltd | Compound and its use for the treatment of alpha1-antitryspin deficiency |
EP4017497A4 (fr) * | 2019-08-23 | 2024-01-10 | pH Pharma Co., Ltd. | Utilisation d'un inhibiteur de l'élastase neutrophile dans les maladies pulmonaires |
CN111978179A (zh) * | 2020-08-27 | 2020-11-24 | 青岛科技大学 | 一种6-羟基己酸酯的合成方法 |
WO2022076881A1 (fr) * | 2020-10-09 | 2022-04-14 | The Regents Of The University Of California | Méthodes de traitement de la maladie d'alzheimer à l'aide d'inhibiteurs d'époxyde hydrolase soluble à liaison étroite lents |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUT42077A (en) * | 1985-06-03 | 1987-06-29 | Squibb & Sons Inc | Process for producing diesters of 2-tioxo- or 2-oxo-pyrimidine-1,5-dicarboxylic acid and 1-acyl-pyrimidine-5-carboxylic acids and esters |
US4738965A (en) * | 1987-02-03 | 1988-04-19 | Institut Organischskogo Sinteza Akademii Nauk Ssr | 2-oxo-4-(2'-difluoromethylthiophenyl)-5-methoxycarbonyl-6-methyl-1,2,3,4-tetrahydropyrimidine |
GB9214053D0 (en) | 1992-07-02 | 1992-08-12 | Ici Plc | Heterocyclic amides |
US6235760B1 (en) * | 1996-03-25 | 2001-05-22 | Smithkline Beecham Corporation | Treatment for CNS injuries |
DK1210344T3 (da) * | 1999-08-19 | 2006-03-06 | Nps Pharma Inc | Heteropolycykliske forbindelser og anvendelser deraf som metabotrope glutamatreceptorantagonister |
MY125533A (en) | 1999-12-06 | 2006-08-30 | Bristol Myers Squibb Co | Heterocyclic dihydropyrimidine compounds |
GB0219896D0 (en) | 2002-08-27 | 2002-10-02 | Bayer Ag | Dihydropyridine derivatives |
GB2392910A (en) * | 2002-09-10 | 2004-03-17 | Bayer Ag | 2-Oxopyrimidine derivatives and their use as human leukocyte elastase inhibitors |
EP1546113B1 (fr) | 2002-09-10 | 2013-05-01 | Bayer Intellectual Property GmbH | Derives de pyrimidinone utilises comme agents therapeutiques contre des processus inflammatoires aigus et chroniques, ischemiques et de remodelage |
EP1539710B1 (fr) | 2002-09-10 | 2010-10-27 | Bayer Schering Pharma Aktiengesellschaft | Derives heterocycliques |
US7166603B2 (en) | 2003-07-23 | 2007-01-23 | Bristol-Myers Squibb Co. | Dihydropyrimidone inhibitors of calcium channel function |
ES2428503T3 (es) | 2004-02-26 | 2013-11-08 | Bayer Intellectual Property Gmbh | 1,4-Diaril-dihidropirimidin-2-onas y su uso como inhibidores de elastasa de neutrófilos humanos |
CA2557271C (fr) * | 2004-02-26 | 2012-08-21 | Bayer Healthcare Ag | 1,4-diaryl-dihydropyrimidin-2-ones et leur utilisation en tant qu'inhibiteurs de l'elastase du neutrophile humaine |
CN1938286A (zh) * | 2004-03-29 | 2007-03-28 | 默克公司 | 作为11-β-羟甾类脱氢酶-1抑制剂的二芳基三唑 |
GB0502258D0 (en) | 2005-02-03 | 2005-03-09 | Argenta Discovery Ltd | Compounds and their use |
GB0512940D0 (en) | 2005-06-24 | 2005-08-03 | Argenta Discovery Ltd | Compounds and their use |
GB0520743D0 (en) | 2005-10-12 | 2005-11-23 | Argenta Discovery Ltd | Compounds and their use |
WO2007129060A1 (fr) | 2006-05-04 | 2007-11-15 | Argenta Discovery Limited | Tétrahydropyrrolopyrimidinediones et leur utilisation comme inhibiteurs de l'élastase neutrophile humaine |
US20100010024A1 (en) | 2006-07-01 | 2010-01-14 | Bayer Healthcare Ag | Use of1,4-diaryl-dihydropyrimidine-2-on derivatives for treating pulmonary arterial hypertension |
US20110003858A1 (en) | 2006-09-04 | 2011-01-06 | Bergstroem Lena | Multimeric heterocyclic compounds useful as neutrophil elastase inhibitors |
DE102008022521A1 (de) * | 2008-05-07 | 2009-11-12 | Bayer Schering Pharma Aktiengesellschaft | 1,4-Diaryl-pyrimidopyridazin-2,5-dione und ihre Verwendung |
BRPI0821027B8 (pt) * | 2007-12-20 | 2021-05-25 | Bayer Ip Gmbh | 4-(4-ciano-2-tioaril)di-hidropirimidinonas para tratamento e/ou prevenção de lesões do pulmão e do sistema cardiovascular, seu processo de preparação e seu uso, e medicamento |
DE102009016553A1 (de) * | 2009-04-06 | 2010-10-07 | Bayer Schering Pharma Aktiengesellschaft | Sulfonamid- und Sulfoximin-substituierte Diaryldihydropyrimidinone und ihre Verwendung |
-
2008
- 2008-12-09 BR BRPI0821027A patent/BRPI0821027B8/pt active IP Right Grant
- 2008-12-09 NZ NZ586263A patent/NZ586263A/en unknown
- 2008-12-09 CN CN201310122598.7A patent/CN103204815B/zh active Active
- 2008-12-09 JP JP2010538407A patent/JP5519526B2/ja active Active
- 2008-12-09 SG SG10201604819TA patent/SG10201604819TA/en unknown
- 2008-12-09 EP EP08864824A patent/EP2234985B1/fr active Active
- 2008-12-09 CN CN2008801216561A patent/CN101903356B/zh active Active
- 2008-12-09 MX MX2010006033A patent/MX2010006033A/es active IP Right Grant
- 2008-12-09 KR KR1020107016069A patent/KR101649381B1/ko active Application Filing
- 2008-12-09 ES ES08864824T patent/ES2382143T3/es active Active
- 2008-12-09 AU AU2008340733A patent/AU2008340733B9/en active Active
- 2008-12-09 AT AT08864824T patent/ATE548355T1/de active
- 2008-12-09 MY MYPI2010002687A patent/MY150285A/en unknown
- 2008-12-09 SG SG2012094132A patent/SG186679A1/en unknown
- 2008-12-09 US US12/809,781 patent/US8288402B2/en active Active
- 2008-12-09 PL PL08864824T patent/PL2234985T3/pl unknown
- 2008-12-09 RS RS20120213A patent/RS52270B/en unknown
- 2008-12-09 CA CA2709786A patent/CA2709786C/fr active Active
- 2008-12-09 SI SI200830619T patent/SI2234985T1/sl unknown
- 2008-12-09 DK DK08864824.1T patent/DK2234985T3/da active
- 2008-12-09 WO PCT/EP2008/010411 patent/WO2009080199A1/fr active Application Filing
- 2008-12-09 KR KR1020167021839A patent/KR101712786B1/ko active IP Right Grant
- 2008-12-09 RU RU2010129724/04A patent/RU2497813C2/ru active
- 2008-12-09 PT PT08864824T patent/PT2234985E/pt unknown
- 2008-12-11 CL CL2008003691A patent/CL2008003691A1/es unknown
- 2008-12-11 PE PE2008002054A patent/PE20091429A1/es active IP Right Grant
- 2008-12-11 UY UY31526A patent/UY31526A1/es active IP Right Grant
- 2008-12-15 AR ARP080105447A patent/AR069765A1/es active IP Right Grant
- 2008-12-18 JO JO2008569A patent/JO2756B1/en active
- 2008-12-19 TW TW097149556A patent/TWI455715B/zh not_active IP Right Cessation
-
2010
- 2010-05-13 IL IL205742A patent/IL205742A/en active IP Right Grant
- 2010-05-28 EC EC2010010216A patent/ECSP10010216A/es unknown
- 2010-06-02 SV SV2010003581A patent/SV2010003581A/es unknown
- 2010-06-02 DO DO2010000165A patent/DOP2010000165A/es unknown
- 2010-06-02 CR CR11472A patent/CR11472A/es unknown
- 2010-06-02 CO CO10066579A patent/CO6280490A2/es not_active Application Discontinuation
- 2010-06-15 ZA ZA2010/04239A patent/ZA201004239B/en unknown
- 2010-06-16 MA MA32921A patent/MA31920B1/fr unknown
- 2010-06-18 TN TN2010000288A patent/TN2010000288A1/fr unknown
-
2011
- 2011-01-21 HK HK11100646.5A patent/HK1146485A1/xx unknown
-
2012
- 2012-05-29 HR HRP20120457AT patent/HRP20120457T1/hr unknown
- 2012-05-31 CY CY20121100495T patent/CY1112813T1/el unknown
- 2012-09-12 US US13/612,435 patent/US8889700B2/en active Active
-
2013
- 2013-09-02 HK HK13110227.9A patent/HK1183018A1/xx unknown
-
2014
- 2014-10-23 US US14/522,510 patent/US9174997B2/en active Active
- 2014-11-18 IL IL235754A patent/IL235754A/en active IP Right Grant
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA31920B1 (fr) | 4-(4-cyano-2-thioaryle)-dihydropyrimidinone et son utilisation | |
MA31570B1 (fr) | Oxazolidinones substitués et leur utilisation | |
MA33123B1 (fr) | 2-acetamido-5-aryl-1,2,4-triazolones substitues et leur utilisation | |
MA32226B1 (fr) | Compositions et leurs procedes de preparation et d'utilisation | |
MA30914B1 (fr) | Dihydropyrazolones substituees utilisees dans le traitement de maladies cardiovasculaires et hematologiques. | |
MA34721B1 (fr) | Acides carboxyliques 1-benzylcycloalkyle substitués et leur utilisation | |
MA31231B1 (fr) | Anticorps anti-robo4 et utilisations de ceux-ci | |
HK1096392A1 (en) | Substituted heterocycles | |
MA31535B1 (fr) | (oxazolidinon-5-yl-méthyl)-2-thiophène-carboxamides substitués et leur utilisation dans le domaine de la coagulation sanguine | |
LTC1781298I2 (lt) | Farmacinės kompozicijos, turinčios benzoksazino, skirtos respiracinių ligų gydymui | |
MA30868B1 (fr) | Derives de 2-aminocarbonyl-pyridine | |
WO2006105516A3 (fr) | Compositions et procedes pour le diagnostic et le traitement de troubles neuropsychiatriques | |
WO2007109236A8 (fr) | Empreintes digitales micro-arn pendant une mégacaryocytopoïese | |
MA27794A1 (fr) | Dihydroquinazolines substituees a proprietes antivirales | |
JO2828B1 (en) | Anti-Hepsidine antibodies and their uses | |
DE502006007526D1 (de) | Antimikrobielles medizintechnisches produkt, verfahren zu seiner herstellung und verwendung | |
SG171599A1 (en) | Blood group antigens of different types for diagnostic and therapeutic applications | |
FR2886851B1 (fr) | Composition a base d'une avermectine et de metronidazole notamment pour le traitement de la rosacee | |
MA37742B1 (fr) | Dérivés d'oestra-1,3,5 (10), 16-tétraène substitués en position 3, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la fabrication de médicaments | |
MA38349A1 (fr) | Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3) | |
MA33290B1 (fr) | Pipéridines substituées | |
MA30039B1 (fr) | Nouveaux derives de furopyrimidines a substitution acyclique et leur utilisation pour traiter des maladies cardiovasculaires | |
WO2006060542A3 (fr) | Formulations de benzoxazoles substitues | |
DE502007004579D1 (de) | Aryl-substituierte heterozyklen und ihre verwendung | |
DK1838716T3 (da) | Olanzapinpamota-dihydrat |